Navigation Links
OncoSec Medical Promotes Veronica Vallejo to Chief Financial Officer
Date:2/19/2013

SAN DIEGO, Feb. 19, 2013 /PRNewswire/ -- OncoSec Medical Inc. (OTCBB: ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumor cancers, announced that Vice President and Controller, Veronica Vallejo has been promoted to Chief Financial Officer effective February 8, 2013.

(Logo: http://photos.prnewswire.com/prnh/20110314/MM64943LOGO)

"Veronica has been an integral part of our team since the inception of OncoSec and this promotion is well deserved. Her strategic insights and strong financial acumen will be valuable to the future success and growth of the company," said Punit Dhillon , President and CEO.

Veronica has over fifteen years of public accounting experience and has worked for nearly a decade in a senior management position. She has extensive experience in public company operations and all financing and accounting functions. Veronica holds a B.S. in Business Administration with an emphasis in accounting from San Diego State University.  She is a certified public accountant and a member of the American Institute of Certified Public Accountants.

About OncoSec Medical Inc.

OncoSec Medical Inc. is a biopharmaceutical company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumor cancers. ImmunoPulse and NeoPulse therapies address an unmet medical need and represent a potential solution, for less invasive and less expensive therapies that are able to minimize detrimental effects resulting from currently available cancer treatments such as surgery, systemic chemotherapy or immunotherapy and other treatment alternatives.  OncoSec Medical's core technology is based upon its proprietary use of an electroporation platform to dramatically enhance the delivery and uptake of a locally delivered DNA-based immunocytokine (ImmunoPulse) or chemotherapeutic agent (NeoPulse). Treatment of various solid cancers using these powerful and targeted anti-cancer agents has demonstrated selective destruction of cancerous cells while sparing healthy normal tissues during early and late stage clinical trials. OncoSec's clinical programs include three Phase II clinical trials for ImmunoPulse targeting lethal skin cancers. More information is available at http://www.oncosec.com/.

This press release contains forward looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such "forward looking statements." Forward looking statements are based on management's current preliminary expectations and are subject to risks and uncertainties which may cause our results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include our ability to raise additional funding, our ability to acquire, develop or commercialize new products, uncertainties inherent in pre-clinical studies and clinical trials, unexpected new data, safety and technical issues, competition and market conditions. These and additional risks and uncertainties are more fully described in OncoSec Medical's filings with the Securities and Exchange Commission. Undue reliance should not be placed on forward looking statements which speak only as of the date they are made. OncoSec Medical disclaims any obligation to update any forward looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.


'/>"/>
SOURCE OncoSec Medical Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. OncoSec Medical to Present at the 15th Annual BIO CEO & Investor Conference
2. OncoSec Medical to Present at Noble Financial Capital Markets Ninth Annual Equity Conference on January 22
3. OncoSec Medical Announces $7.2 Million Public Offering
4. OncoSec Medical to Present Data at DNA Vaccines 2012 Conference
5. OncoSec Medical Reports Positive Preliminary Efficacy Results from Phase II Study of ImmunoPulse in Metastatic Melanoma Patients
6. OncoSec Medical Reports Positive Interim Efficacy Results from Phase IV Study of NeoPulse in Skin Cancer Patients
7. OncoSec to Present at Upcoming Healthcare and Investor Conferences
8. OncoSec Granted New Patent from China
9. OncoSec to Present at the Rodman & Renshaw 2012 Annual Global Investment Conference
10. OncoSec Featured on KTVU-TV News and in San Francisco Chronicle
11. OncoSec OMS ElectroChemotherapy for Head and Neck Cancer Shows Enhanced Quality of Life in Two Randomized Phase III Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... Breast Cancer Therapeutics in Asia-Pacific Markets to 2021 ... breast cancer market will experience considerable expansion from $1.9 billion ... Annual Growth Rate (CAGR) of 8.5%. --> Breast ... that the Asia-Pacific (APAC) breast cancer ... to $3.4 billion by 2021, at a Compound Annual Growth ...
(Date:2/11/2016)... PLAD, Inc. (OTC Pink: PLAD) is pleased to announce ... company targets, are adding key personnel to their national ... United States Patent and Trademark Office for the characters ... of PLAD, Inc.  In January, PLAD established their presence ... with two new customers, Cumberland Goodwill EMS and Meadville ...
(Date:2/11/2016)... 2016  M3 Biotechnology Inc., spurred by a major "team investment" by Bruce Montgomery , ... an oversubscribed Series A-Round, according to CEO Leen Kawas , PhD. ... ... ... Kawas said the ...
Breaking Medicine Technology:
(Date:2/11/2016)... City, FL (PRWEB) , ... February 11, 2016 ... ... announced the commencement of a master charity program created to assist the people ... 60 days, working closely with nonprofit organizations and community leaders. Their hope is ...
(Date:2/11/2016)... ... February 11, 2016 , ... Duterte Insurance Group, serving ... introduces a new charity campaign to raise funds for Ronald McDonald House Charities. ... https://donate.rmhc.org/ . , Ronald McDonald House (RMH) is an internationally renowned nonprofit ...
(Date:2/11/2016)... ... ... Be Well Medical Group (Be Well) is pleased to announce ... South Columbus St, Suite 201, Alexandria, VA. Be Well Medical Group is a concierge ... of their homes, offices or at the practices’ local office. It is also one ...
(Date:2/11/2016)... ... February 11, 2016 , ... Food Labeling for American ... and wellness best practices in the past couple of decades, and food manufacturers ... Heart Month, which acts as an exceptional opportunity to revise food labels and ...
(Date:2/10/2016)... ... 10, 2016 , ... President Obama’s budget proposal yesterday enables ... medical services via telehealth, estimated to generate more than $160 million in savings ... many years. Although there is more to be done, this represents an ...
Breaking Medicine News(10 mins):